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Unlocking the Mysteries of Diastolic Function
Deciphering the Rosetta Stone 10 Years Later
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It has now been a quarter of a century since the first description by Kitabatake and his associates of the use of
echo-Doppler to characterize the transmitral flow velocity curves in various disease states. A decade ago we de-
scribed the role of echocardiography in the “Evaluation of Diastolic Filling of Left Ventricle in Health and Disease:
Doppler Echocardiography Is the Clinician’s Rosetta Stone.” Over the ensuing decade, advances in echo-Doppler
have helped to further decipher the morphologic and physiological expression of cardiovascular disease and un-
lock additional mysteries of diastology. The purpose of this review is to highlight the developments in echo-
Doppler and refinements in our knowledge that have occurred over the past decade that enhance our under-
standing of diastology. (J Am Coll Cardiol 2008;51:679–89) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.09.0611
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ocho-Doppler with its high spatial and unequaled temporal
esolution has revolutionized our clinical access to cardiac
hysiology and pathophysiology. It has now been a quarter
f a century since the first description by Kitabatake et al.
1) of the use of echo-Doppler to characterize the transmi-
ral flow velocity curves in various disease states. A decade
go we described the role of echocardiography in the
Evaluation of Diastolic Filling of Left Ventricle in Health
nd Disease: Doppler Echocardiography Is the Clinician’s
osetta Stone” (2), the Rosetta Stone here being used as a
etaphor to refer to anything that is a critical key to a
rocess of decryption or translation of a difficult problem.
he term “diastology” continues to refer to the science and
rt of characterizing left ventricular (LV) relaxation, filling
ynamics, and their integration into clinical practice. The
hysiology of diastole remains valid as discussed a decade
go (2). However, over the ensuing decade, advances in
cho-Doppler have helped to further decipher the morpho-
ogic and physiological expression of cardiovascular disease
nd unlock additional mysteries of diastology. The purpose
f this review is to highlight the developments in echo-
oppler and refinements in our knowledge that have
ccurred over the past decade that enhance our understand-
ng of diastology. Developments include:
rom the *Division of Cardiovascular Disease, Mayo Clinic, Scottsdale, Arizona; and
Mayo Clinic, Rochester, Minnesota.m
Manuscript received August 9, 2007; revised manuscript received September 20,
007, accepted September 24, 2007.. Epidemiologic studies highlighting the prevalence and
prognosis of those with diastolic dysfunction with and
without clinical symptoms
. The concept of “continuity disease” and “clustering”
. Noninvasive measures of the acuity and chronicity of
LV filling pressure elevation
. Concepts of blood flow propagation within the LV
. Stress testing, diastolic function response
. The integration of echo-Doppler measures of diastolic
function into a therapeutic treatment paradigm
. Better understanding of the relationship of myocardial
form with function and the ability to characterize
measures of myocardial mechanics
pidemiology
ver the past decade, there has been a steady rise in the
revalence of heart failure in those with a preserved LV
jection fraction (diastolic heart failure) (3). By the seventh
ecade of life, the incident cases of heart failure with a
reserved LV ejection fraction approach, and by the eighth
ecade of life exceed, those of heart failure with reduced LV
jection fraction (4). The survival of patients with the
linical syndrome of heart failure is similar in those with
ersevered versus those with a reduced LV ejection fraction
5). The understanding of diastology has become even more
ermane to the practice of medicine as our understanding
volves of the profound adverse clinical consequences of
linically overt diastolic dysfunction and that the prevalence
f asymptomatic diastolic dysfunction in the general com-
unity is not insignificant, a finding being noted in approx-
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als 45 years of age (6,7). Note,
diastolic dysfunction and dia-
stolic heart failure are not inter-
changeable terms. Diastolic heart
failure is used to describe clini-
cally symptomatic individuals
with the characteristic syndrome
of heart failure in the setting of a
normal ejection fraction, whereas
diastolic dysfunction simply de-
notes an abnormality of dia-
stolic function and does not
characterize the clinical status
of an individual.
“Continuity Disease”
The cardiovascular system is a
continuous system of reservoir,
pump, and vessels. An ailment in
one part of the system will influ-
ence all contiguous components.
An increase in vascular and ven-
tricular stiffness is an integral
component of aging (8 –12).
Vascular and ventricular stiffness
appear to be a precipitant to im-
aired cardiac performance and clinical prognosis. Vascular
tiffness histologically is associated with changes in vessel
all architecture and perivascular fibrosis (13). A change in
he extracellular matrix of the myocardium, with the for-
ation of excess collagen tissue and serologic evidence of an
ctive fibrotic process, is a characteristic finding in those
ith diastolic dysfunction (14,15). At the cellular level,
here is reduced phosphorylation of sarcomeric proteins (16)
nd at the proteomic level, an isoform change in important
tructural proteins such as titin, which functions to connect
arcomeres at their ends (Z-discs) and participates in cell
ignaling (15,17,18). The change in cardiovascular elastance
s a marker for increased cardiac morbidity, and not surpris-
ngly, it appears to be most prevalent in that segment of the
ommunity most likely to develop the clinical syndrome of
eart failure independent of the underlying LV ejection
raction (11).
Effective arterial elastance (Ea) can be estimated as the
atio of end-systolic pressure/stroke volume (19). End-
ystolic pressure is estimated as (0.9  systolic blood
ressure) and stroke volume the product of the left ventric-
lar outflow tract (LVOT) area and LVOT time velocity
ntegral. During diastole, when the mitral valve is open, the
eft atrium (LA) is exposed to the loading pressure within
he LV. Over time, exposure of the LA to increased filling
ressure will result in its remodeling reflected in the measure
f LA volume. A simple yet robust marker for the chronicity
Abbreviations
and Acronyms
A  A velocity
ACEI  angiotensin-
converting enzyme inhibitor
ARA  aldosterone
receptor antagonist
ARB  angiotensin I
receptor antagonist
DT  deceleration time
DTI  Doppler tissue
imaging
E  E velocity
Ea  arterial elastance
IVRT  isovolumic
relaxation time
LA  left atrium
LV  left
ventricle/ventricular
LVOT  left ventricular
outflow tract
SRivr  strain rate during
the isovolumic relaxation
phase of the cardiac cycle
Vp  mitral inflow
propagation velocityf change in Ea appears to be the LA size. In clinicalractice, LA size expressed as volume indexed to body
urface area is recommended (20,21). The biplane area-
ength or Simpson’s methods are a practical means with
hich to measure LA volume (Fig. 1).
The LA volume can be viewed as a morphologic expres-
ion of LV diastolic dysfunction. Left atrial volume is
egarded as a “barometer” of the chronicity of diastolic
ysfunction and to analogize, LA volume is to diastolic
unction and to all forms of heart disease as the HbA1c is to
iabetes. This simple measure of LA volume provides
ignificant insight into an individual’s risk for the develop-
ent of adverse cardiovascular events including, myocardial
nfarction, stroke, atrial fibrillation, and heart failure (22–
5). Left atrial volume is graded relative to risk, 28 to 33
l/m2  mild; 34 to 39 ml/m2  moderate; and 40
l/m2 high or severe (23). For the practicing cardiologist,
A volume, therefore, may be considered an excellent
Figure 1 Biplane Methods With
Which to Calculate LA Volume
(A) Biplane area length, A1  left atrial (LA) area, 4-chamber view; A2  LA
area, 2-chamber view; L1 and L2: length from midplane of mitral annulus to
superior LA, L  LA length, L1 or L2 whichever is shorter; (B) Biplane Simp-
son’s where the volume of the LA is calculated as the sum of the volume of
each individual disc.
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February 19, 2008:679–89 Unlocking the Mysteries of Diastolic Functioniomarker of the chronicity of diastolic dysfunction and of
ardiovascular disease risk (26).
lood Flow and Myocardial Tissue Velocities
n enlarged LA reflects chronicity of LV filling pressure
levation while Doppler-derived LV filling dynamics, which
eflect acuity, can vacillate moment to moment. An inte-
rative evaluation of acuity and chronicity allows for clinical
taging of diastolic dysfunction (Fig. 2). The strengths and
eaknesses of various parameters used in the evaluation of
V filling pressure are outlined in Table 1 and discussed in
he following text.
The mitral inflow velocity profile is used to initially
haracterize LV filling dynamics. The E velocity (E) repre-
ents the early mitral inflow velocity and is influenced by the
elative pressures between the LA and LV, which, in turn,
re dependent on multiple variables including LA pressure,
V compliance, and the rate of LV relaxation. The A
elocity (A) represents the atrial contractile component of
itral filling and is primarily influenced by LV compliance
nd LA contractility. The deceleration time (DT) of the E
elocity is the interval from peak E to a point of intersection
f the deceleration of flow with the baseline and it correlates
ith time of pressure equalization between the LA and LV
Fig. 3). As the early LA and LV filling pressures either
volve toward or away from equivalence, so will the DT
ither shorten or lengthen respectively.
Diastolic dysfunction is directly related to the reduction
n early LV relaxation compromising the effective transfer of
he blood from the atrial reservoir into the LV cavity. The
eduction in LV relaxation may be characterized through
he evaluation of mitral annular motion, generally with
oppler tissue imaging, which can resolve subtle changes in
V relaxation by identifying a low septal annular early
iastolic mitral annular motion (e=) velocity (10 cm/s).
here are 2 fundamental causes of delayed LV relaxation
nd elevation of early LV filling pressure:
Figure 2 The Natural History
of Diastolic Function and LV Filling
DD  diastolic function; e=  early diastolic mitral
annular velocity; LAP  left atrial pressure; LV  left ventricular.d. The LV chamber is distorted (e.g., infarction, hypertro-
phy, cardiomyopathy, and dyssynergic wall motion),
impairing the effective transfer of blood from the mitral
orifice to the LV apex.
. The LV ejection period is prolonged due to increased
ventricular-arterial afterload.
ncomplete or delayed relaxation causes a delay in the
ransfer of blood from atria to ventricle. The pressures
mpeding forward flow are reflected backward (continuity
trengths and Weaknesses of the Parameterss d in the Evaluation of LV Filling Pr ssure
Table 1 Strengths and Weaknesses of the ParametersUsed in the Evaluation of LV Filling Pressure
Strengths Weaknesses
PW mital inflow 1. Can be obtained
in nearly all patients
2. Diagnostic and
prognostic information
1. Highly pre-load
dependent
2. Quantitative values
influenced by PW sample
volume placement
3. Problematic at high heart
rates, atrial fibrillation,
heart block, paced
rhythms
4. Measurement of DT
when there is a nonlinear
velocity decline
DTI (e=) 1. Can be obtained in
most patients
2. Early marker of
diastolic dysfunction
3. Not influenced by
changes in heart rate
4. Primarily load
independent in disease
states
1. Influenced by local
changes in wall motion
(infarction)
2. Possible influence by
pericardial adhesions
(note, possible strength
too in helping to
differentiate constriction
from restriction)
PV flow 1. The relationship of
PVAR to mitral A
duration is the only
marker specific for
elevation in LVEDP
2. Complements PW
mitral inflow and
particularly helpful
when there is E- and
A-wave fusion to help
classify diastolic filling
1. Can be difficult to obtain
adequate signals
2. Influence by changes in
rhythm (atrial fibrillation)
Mitral inflow
propagation
1. Provides temporal,
velocity, and spatial
information
1. Observer reproducibility
2. Dependent on pre-load
and cardiac chamber size
IVRT 1. Represents the earliest
phase of diastole
1. Requires defining timing
of 2 separate events AVC
and MVO that may need
slightly different imaging
planes
2. Measurement
reproducibility
LA volume 1. Provides morphologic
and physiological
evidence for chronic
elevation in filling
pressure
2. Severity scale based on
clinical outcomes
1. Chronic volume overload
(e.g., anemia, athletic
heart, compensated
valve disease) can result
in an increase in LA
volume yet a normal LV
filling pressure
VC  aortic valve closure; DT  mitral E-wave deceleration time; DTI  Doppler tissue imaging;
=  septal annular early diastolic tissue velocity; IVRT  isovolumic relaxation time; LA  left
trial; LV  left ventricular; LVEDP  left ventricular end-diastolic pressure; MVO  mitral valve
pening; PV  pulmonary vein; PVAR  pulmonary vein A reversal duration; PW  pulsed wave.isease) into the atria and pulmonary veins. Early in the
e
(
e
r
i
i
v
t
m
t
H
t
v
v
d
(
i
a
m
t
s
d
p
t
a
r
e
r
o
w
L
o
w
a
a
r
v
o
o
t
m
i
d
l
r
t
d
p
P
m
i
a
w
o
i
d
D
m
t
a
682 Lester et al. JACC Vol. 51, No. 7, 2008
Unlocking the Mysteries of Diastolic Function February 19, 2008:679–89volution of “diastolic dysfunction” the delay in emptying
DT 240 ms) is partially compensated by a more vigorous
nd-diastolic atria contraction, and, hence, the E/A ratio is
educed (0.9, grade I diastolic dysfunction). With further
ncreased impedance to atrial emptying, atrial pressure
ncreases, and the relative difference between atria and
entricular pressure decreases (DT shortens). As a result,
he E velocity and E/A ratio will now increase, and the
itral inflow velocity profile may appear normal (E/A 0.9
o 1.5 and DT 160 to 240, grade II diastolic dysfunction).
owever, the e= velocity will remain reduced, identifying
he underlying LV relaxation abnormality. A reduced e=
elocity, increased E/e= ratio, and associated increased LA
olume (28 ml/m2) can, therefore, be readily used to
iscriminate an individual with normal versus grade II
pseudonormal) diastolic dysfunction (27,28). Similarly,
ndividuals with grade III diastolic dysfunction, E/A 2,
nd DT 160 ms who are able to favorably influence their
itral inflow velocity profile with hemodynamic manipula-
ion, often the Valsalva maneuver, declare themselves of less
evere diastolic dysfunction than those with grade IV
iastolic dysfunction who have an irreversible restrictive
attern and a very poor prognosis.
Insights into LV diastolic function can be deciphered
hrough the evaluation not only of the relationship of the
mplitude of E to e= but also through the evaluation of the
elationship of the timing of the onset of E to the onset of
=. Normally mitral inflow is initiated with rapid LV
elaxation and “suction” of blood into the LV. When this
ccurs, the onset of e= will be slightly before or simultaneous
ith the onset of E. If, however, LA pressure is elevated and
V relaxation reduced, E velocity onset may precede the
nset of e=. These timing relationships have been correlated
ith LV filling pressure (29,30) (Fig. 4).
A limitation of the use of the e= velocity is the fact that
Figure 3 The Mitral Inflow Velocity Profile
A  atrial component of mitral filling;
DT  deceleration time; E  early diastolic mitral inflow velocity.cquisition is generally from a single site, the mitral annulus,nd values obtained assume that they reflect global LV
elaxation. Although much less practical, the average e=
elocity from multiple sites enhances the test characteristics
f the E/e= ratio to predict LV filling pressures (31). The use
f 2-dimensional speckle tracking technologies allows for
he characterization of global parameters of myocardial
otion. A measure of global diastolic strain rate during the
sovolumic relaxation phase of the cardiac cycle (SRivr)
irectly measures a global myocardial relaxation parameter
ess influenced by annular and valvular pathology. The
elationship of the mitral E-wave velocity to SRivr appears
o provide enhanced discriminatory power with which to
etect an elevation in mean pulmonary capillary wedge
ressure when compared with the E/e= ratio (Fig. 5) (32).
ulmonary vein flow. The ability to evaluate myocardial
otion with high temporal resolution (Doppler tissue
maging) and thus detect the underlying LV relaxation
bnormality (low e=) present with little exception in those
ith diastolic dysfunction has minimized, but not relegated
bsolete, the utility of the evaluation of pulmonary vein flow
n the assessment of LV filling pressure. Over the past
ecade, insights into the physiology of the pulmonary vein
oppler velocity profile has evolved (33). The parameters
easured and insights into diastolic function gained from
heir interpretation, however, remain as discussed a decade
go (2). It is worthy of note that if the mitral inflow velocity
Figure 4 Transmitral Doppler and
Tissue Doppler of the Mitral Annulus
(A) Normal left ventricular filling pressure. (Left) Mitral inflow velocity profile;
(right) septal annular tissue velocity profile. (B) Elevated left ventricular filling
pressure. e=  early diastolic mitral annular velocity; other abbreviations as in
Figure 3.
p
a
v
a
L
p
I
t
o
e
b
a
i
d
I
a
d
I
c
M
m
c
o
r
l
t
d
v
fi
t
s
r
s
m
b
t
m
(
r
c


r
a
m
o
t
p
d
P
A
m
d
c
v
p
p
f
d
683JACC Vol. 51, No. 7, 2008 Lester et al.
February 19, 2008:679–89 Unlocking the Mysteries of Diastolic Functionrofile indicates a predominant relaxation abnormality with
low E/e= ratio (normal mean LA pressure), a pulmonary
ein flow duration greater than mitral inflow duration at
trial contraction may indicate an earlier stage of reduced
V compliance as well as increased LV end-diastolic
ressure.
sovolumic relaxation time (IVRT). The IVRT is the
ime interval between aortic valve closure and mitral valve
pening. The transducer is placed in the apical position with
ither a pulsed or continuous wave Doppler sample placed
etween the aortic and mitral valves. A normal IVRT is
pproximately 70 to 90 ms. The IVRT will lengthen with
mpaired LV relaxation and shorten when LV compliance is
ecreased and LV filling pressures are increased. Note the
VRT will vary with heart rate and ventricular function,
nd, thus, absolute values cannot always be interpreted to
ichotomize normal versus abnormal LV filling pressure.
sovolumic relaxation time may be very helpful in following
linical response to various treatment strategies.
itral inflow propagation velocity (Vp). Important in the
echanics of LV diastole are regional differences in myo-
ardial relaxation. Normally there is a wave of relaxation
riginating at the apex and moving toward the base. This
esults in a base-to-apex pressure gradient allowing blood to
iterally be sucked into the LV. With LV diastolic dysfunc-
ion and the associated relaxation abnormality, the regional
Figure 5 Global Strain Rate Profile
Global strain rate (SR) signal (purple, right axis), and mitral velocity (left axis)
tracings by color tissue Doppler from the septal (blue) and lateral side (red) of
the mitral annulus from the same cardiac cycle. Note the SR signal during the
isovolumic relaxation phase of the cardiac cycle (*) and the corresponding
velocity tracings from the mitral annulus recording during the same interval. Aa
 late diastolic velocity; AVC  aortic valve closure; Ea  mitral annulus early
diastolic velocity; GSRa  global strain rate during late left ventricular filling;
GSRe  global strain rate during early left ventricular filling; GSRivr  global
strain rate during the isovolumic relaxation phase of the cardiac cycle period;
MVO  mitral valve opening. Reprinted, with permission, from Wang et al. (32).ifferences in relaxation are less pronounced and the intra-entricular pressure gradient responsible for normal LV
lling reduced or even absent.
Color M-mode of the mitral inflow obtained by placing
he M-mode cursor in the direction of the mitral inflow jet
een on the color Doppler map can be used to evaluate LV
elaxation (34–36). This display will provide temporal,
patial, and velocity information. There have been various
ethods described with which to calculate the Vp from LV
ase (annulus) to apex. A practical approach is to measure
he slope of the line of the first aliasing velocity from the
itral valve plane to approximately 4 cm distal into the LV
normal 50 cm/s) (Fig. 6). Like e=, Vp characterizes LV
elaxation, and not surprising, therefore, the ratio of E/Vp
an be used to estimate LV filling pressure, with an E/Vp
1.5 suggestive of a pulmonary capillary wedge pressure of
15 mm Hg (37,38). Caution in the interpretation of this
atio is recommended in the setting of LV hypertrophy and
small LV cavity size where Vp may be high and this ratio
ay not, therefore, accurately reflect LV filling pressure. In
ur clinical practice, we perform only a qualitative interpre-
ation of the color M-mode mitral inflow velocity only
roviding an estimate of the velocity, temporal, and spatial
istribution of LV filling.
ractical Approach
lthough there are other echocardiographic parameters that
ay be used to characterize diastology, the parameters
iscussed in the preceding text represent those that are
ommonly used in daily practice. The measure of LA
olume is the cornerstone to evaluation for its ability to
rovide insight into the chronicity of elevation of LV filling
ressure and to characterize global cardiovascular risk.
Initial observations of 2-dimensional echocardiographic
eatures often provide diagnostic clues as to the status of
iastolic function. Patients with diastolic dysfunction qual-
Figure 6 Mitral Inflow Propagation Velocity
bpm  beats/min; HR  heart rate.
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Unlocking the Mysteries of Diastolic Function February 19, 2008:679–89tatively may have increased LV wall thickness, an increase
n LA size, and reduced mitral annular motion. The more
uantitative assessment of diastolic function and the “acuity”
easure of LV filling pressure then generally begins by
haracterizing the mitral inflow velocity profile as either
ormal (E/A ratio 0.9 to 1.5, DT 160 to 240 ms), restrictive
E/A ratio typically 2, DT 160 ms), or delayed relax-
tion (E/A ratio 0.9, DT 240 ms). A dilemma exists
hen the mitral inflow velocity profile is characterized as
ormal and the integration of the measures of mitral inflow
ith measures of tissue and other blood flow velocities help
o decipher normal from abnormal diastolic function (Table
). The E/SRivr is an intellectually intriguing parameter
hat with further validation may become standard in the
valuation of LV filling pressures.
Although particular reference is made to the septal mitral
nnular e= velocity, the lateral mitral annular e= velocity may
lso be useful. It must be noted, however, that the lateral e=
elocity generally exceeds the septal e= velocity, and, thus, in
ur practice a lower E/e= cutoff (12 vs. 15) is used to
ichotomize normal from elevated filling pressures when the
ateral e= velocity is used. The E/e= ratio derived from the
eptal e= is preferred (28).
When the mitral inflow velocity profile is characterized as
estrictive, it too is important to integrate these findings
ith measures of mitral annular motion as discussed in the
receding text. With rapid relaxation (health), the LV is
ble to “suck” blood into itself at high velocities and the E/A
atio may exceed 2. Here, however, the rapid relaxation is
learly denoted by a robust annular e= velocity and low E/e=
atio. One important clinical caveat is constrictive pericar-
itis, where the e= velocity may be normal and the E/e= ratio
ow despite an increase in LV filling pressure (“annulus
aradoxus”) (39). A low e= and increase in E/e= ratio
etermination of Diastolic Function Grade
Table 2 Determination of Diastolic Function Grade
Normal
PW-mitral inflow
DT (ms)* 160–240
E/A* 0.9–1.5
Modifiers DTI*
e= (cm/s) 10
E/e= (septal) 1–14
LAVI* (ml/m2) 22  6
Valsalva Negative
PVAR and mitral A duration 30 ms 
(depe
PV flow PVs2  PVd (PVs2 can be
 PVd in young persons)
P
IRVT (ms) 70–90
Mitral inflow propagation
Vp (cm/s) 50
E/Vp 1.5
Most important.
E/A the ratio of the mitral early (E) and atrial (A) components of the mitral inflow velocity profile; LAVI
ein second systolic forward flow velocity; Valsalva positive  E/A ratio to decrease by 0.5 and increasonfirms a reduction in LV diastolic function and an
ncrease in LV filling pressure.
A non–E-wave dominant mitral inflow velocity profile
ssentially excludes demonstrable increases in LV filling
ressure. However, here too a measure of LA volume and e=
s important, as there is a subset of individuals with a mitral
nflow velocity profile characterizing a relaxation abnormal-
ty (grade I) diastolic dysfunction who have an increased LA
olume and/or an increased septal E/e= ratio (15, e.g., E
80 cm/s, A  110 cm/s, e=  4 cm/s, E/e=  20). We
esignate these individuals as having grade Ia diastolic
ysfunction (mild elevation in LV filling pressure).
iastolic Stress Test
patient reporting symptoms of dyspnea in the setting of a
ormal pulmonary evaluation, a negative contemporary
tress test, and normal resting diastolic function often
resents a clinical enigma. Analogous to those with reactive
irways disease, diastolic dysfunction my not be identified
ithout provocation, “diastolic stress test.” The mitral
nnular e= velocity is not significantly altered by changes in
ardiac cycle length. Any change in e= velocity noted
econdary to a change in cardiac cycle length is directly
elated to the transmitral pressure gradient as thus concor-
ant changes in the mitral E-wave velocity are noted (40).
he E/e= ratio is a representation of mean LA pressure and
an be measured during an echocardiographic stress test
41,42). Mean LA pressure with exercise remains within
ormal limits in healthy individuals. Therefore, a measure
f the E/e= ratio during aerobic stress may be useful for
istinguishing patients with cardiac disease and help to
olve the clinical enigma (41–44).
d
e 1)
Moderate
(Grade 2)
Severe
(Grade 3)
Severe
(Grade 4)
0 160–240 160 130
9 0.9–1.5 2.0 2.5
8 5 5
15 20 25
28 35 40
ive Positive Positive Negative
0 ms
on LVEDP)
30 ms 30 ms 30 ms
PVd PVs2  PVd PVs2  PVd PVs2  PVd
90 70 70
50 50 50
5 1.5 1.5 1.5Mil
(Grad
24
0.
10
15
28
Posit
or 3
nding
Vs2 
90
50
1.left atrial volume index; PVd pulmonary vein diastolic forward flow velocity; PVs2 pulmonary
e in A velocity; Vp  mitral inflow propagation velocity; other abbreviations as in Table 1.
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n clinical medicine there are essentially only 2 therapeutic
argets: to improve symptoms and, hence, quality of life, and
o enhance survival, quantity of life. In those with the
linical syndrome of heart failure, it must be emphasized
hat heart failure is not a diagnosis but rather a constellation
f signs and symptoms representing a final common path-
ay of a heterogeneous group of diseases (45). In those
resenting with the clinical syndrome of heart failure, one
ust initiate a meticulous search for the underlying etiology
nd precipitant causes. As such, the treatment strategy must
e first and foremost directed toward the identification and
orrection of the underlying precipitating and pathogenic
echanism(s) (Table 3). This highlights the need to indi-
idualize the therapeutic approach.
ondisease-specific (general) therapeutic approach. Gen-
ral, nondisease-specific therapies are then used to help
etter control symptoms. These therapies may too be
ailored to an outcome of a more favorable diastolic function
rade (Fig. 2). In the normal heart, as heart rate increases
here is an increase in contractility and faster relaxation. In
yocardial disease, there is a slower LV pressure decline
nd incomplete pressure restitution, and thus higher LV
iastolic pressure and reduced coronary flow reserve. For
ndividuals with grade I and II diastolic dysfunction, the
uration of diastole is critical, and beta-blockers or rate-
lowing calcium-channel blockers often provide a favorable
ymptomatic response allowing more time for ailing diastole
o do its work either at rest and/or to truncate an exercise-
nduced increase in heart rate. In contrast, in patients with
rade III or IV diastolic dysfunction, LV filling may be
omplete by mid-diastole. Such patients have a fixed stroke
olume, and empirically slowing the heart rate into the 50s
nd 60s may result in a further reduction in cardiac output
nd a worsening of the clinical symptom complex. There-
ommon Etiologies of Diastolic Heart Failure
Table 3 Common Etiologies of Diastolic Heart Failure
Etiology of Diastolic
Heart Failure Management
Systemic hypertension Adequate control and monitoring of blood
pressure
Ischemic heart disease Relieve ischemic (acute or chronic)
Diabetic heart disease Good blood sugar control
Obesity/metabolic syndrome Reduce weight, lipid management
Sleep-disordered breathing CPAP
Valvular heart disease Early intervention
Constrictive pericarditis Pericardiectomy
Restrictive cardiomyopathy Symptomatic treatment, cardiac transplant
Hypertrophic cardiomyopathy Pharmacotherapy, relieve outflow obstruction
Infiltrative disorders
(e.g., amyloid)
(e.g., stem cell transplant)/disease-specific
treatment
Storage disease
(e.g., hemachromatosis)
(e.g., phlebotomies)/disease-specific
treatment
PAP  continuous positive airway pressure.ore, in these patients, the initiation of beta-blocker therapyhould be monitored closely and initiated with small doses
ith small increments.
Diuretics have a salutary effect on symptoms by reducing
ntravascular volume and steering the LV to a more favor-
ble position on its end-diastolic pressure volume relation
nd reducing pericardial restraint (Fig. 7). Therapies that
esult simply in a change in position on the LV end-
iastolic pressure volume curve without imparting a right
nd downward curve shift are likely analogous to treating a
ever with acetaminophen; they improve the symptom but
o not influence the underlying root cause and, hence, have
o impact on long-term survival. Those able to respond
avorably to hemodynamic manipulation do, however, ap-
ear to have a better prognosis (46–48) as they likely
epresent those with less severe disease. Intriguing are
herapies that may favorably influence the underlying final
ommon pathway, the increase in vascular and ventricular
tiffness.
reating the final common pathway, vascular-ventricular
tiffness. The presence of diastolic dysfunction regardless
f symptom status portends significant risk for future
dverse cardiovascular outcomes, and the absence of patient
oiced complaints does not support the absence of thera-
eutic intervention. In those with clinically occult diastolic
ysfunction, the initial therapeutic approach is identical to
hat recommended for those with symptoms: identify and
reat the underlying etiology and precipitant cause(s). For
xample, the treatment of hypertension in those with
linically occult diastolic dysfunction results in an objective
mprovement in diastolic function (49). Neurohormonal
odulation of the renin-angiotensin-aldosterone system
s currently the only therapy with a salutary effect on
ome of the pathophysiological mechanisms responsible for
he increase in vascular and ventricular stiffness (50,51).
Figure 7 The LVEDP Volume Relationship
Purple  more favorable position; Green  less favorable position.
LV  left ventricular; LVEDP  left ventricular end-diastolic pressure.
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ensin I receptor antagonists (ARBs), and aldosterone re-
eptor antagonists (ARAs), independent of their hemody-
amic effects, mediate potentially favorable effects of
educed smooth muscle cell growth, prevention of collagen
eposition, reduced growth factor expression, and regres-
ion of myocardial fibrosis (52–56). The finding of an
nlarged LA in the absence of a definitive underlying
recipitating cause (e.g., mitral regurgitation or a high
utput state) is a call to arms, and our approach beyond
herapeutic lifestyle intervention is to initiate ACEI or ARB
herapy currently targeting a blood pressure of 110/75 mm
g. Of interest, ACEI therapy may result in favorable
emodeling of the LA independent of their influence on
lood pressure (57).
In those with the clinical syndrome of heart failure and a
reserved LV ejection fraction, an evidence-based approach
o treatment is lacking; however, there is information
upporting a clinical judgment-based approach to manage-
ent. The CHARM-Preserved (Effects of Candesartan in
atients With Chronic Heart Failure and Preserved Left-
entricular Ejection Fraction) trial, a prospective outcome
rial evaluating a treatment strategy (candesartan) solely for
ndividuals with heart failure and a normal ejection fraction,
ncluded a heterogeneous etiologic classification of heart
ailure (58). The findings, however, were promising, show-
ng a significant reduction in hospitalization for heart failure
nd a strong trend toward significance in the primary
utcome of death or hospital admission for heart failure.
he PEP-CHF (Perindopril in Elderly People with
hronic Heart Failure) study evaluated individuals 70
ears of age with a clinical diagnosis of heart failure and a
reserved LV ejection fraction. Here too the findings were
romising, showing an improvement in symptoms and
xercise capacity along with fewer hospitalizations in those
n the active treatment group noted in the first year of
ollow-up (59). We await the results of the I-PRESERVE
Irbesartan in Heart Failure with Preserved Systolic Func-
ion) trial, where inclusion defined a more discriminate
atient population (60).
Statins similarly have touted favorable pleiotropic effects
oo on diastolic function, and the art of medicine suggests
hat a low threshold for the use of statins may be appropriate
61,62). Beta-blockers as discussed in the preceding text are
ften helpful in the symptomatic management of patients
ith diastolic heart failure. However, several clinical trials,
gain including individuals with heterogeneous pathophys-
ological mechanisms for heart failure, have shown that
rimarily those with too low an LV ejection fraction may
erive a survival advantage with beta-blocker therapy
63,64). The SENIORS (Study of the Effects of Nebivolol
ntervention on Outcomes and Rehospitalisation in Seniors
ith Heart Failure) trial suggests that the elderly with heart
ailure can tolerate beta-blocker therapy and derive a favor-
ble clinical benefit (reduction is composite of death or
ardiovascular hospitalization) particularly if target doses are pchieved (65). This trial did include patients with preserved
V ejection fractions (approximately one-third), but the
ean LV ejection fraction for each group was approximately
5%. Other trials have suggested that the use of beta-
lockers in those with heart failure and a preserved LV
jection provides mortality benefit (66).
Endothelin influences myocardial inotropic and lusiotro-
ic function, and intellectually intriguing is the potential
ole of an endothelin receptor antagonist in the manage-
ent of patients with heart failure (67,68). However, when
valuated in an etiologically heterogeneous group of heart
ailure patients, endothelin receptor blockers when added to
tandard therapy did not improve outcome, currently cast-
ng doubt on the use of endothelin receptor blockers for the
anagement of heart failure (69–71). Further pathophysi-
logical insight into disease inception may influence novel
herapeutic strategies targeting the vasculature, with end
oints encoded somewhere in the cardiovascular structural
nd functional continuum. For example, it has recently been
roposed that endothelial cells may, in fact, transition into
esenchymal cells and thus contribute fibroblasts to the
rocess of cardiac fibrosis (72). In a mouse model of pressure
verload and chronic allograft rejection, recombinant hu-
an bone morphogenic protein-7 could preserve the endo-
helial phenotype and retard the progression of fibrosis (72).
n addition, preliminary small animal studies suggest that
hosphodiesterase-5A inhibition with oral sildenafil may
uppress chamber and myocyte hypertrophy, remodeling,
nd fibrosis by deactivating various hypertrophy signaling
athways (73,74). Additional preliminary and novel strate-
ies directed at influencing the final common pathway of
isease hold promise (75). Definitive comments on the
mpact of beta-blockers, ACEIs, ARBs, ARAs, statins, and
ther pharmacologic therapies in those with heart failure
nd a preserved LV ejection fraction are pending prospec-
ive randomized clinical trials. Until then, such individual-
zed treatments encompass clinical judgment-based thera-
eutic strategies.
here Are We Going?
lthough it is practical to classify cardiac dysfunction as
ither systolic or diastolic, such a classification is based on
hysiological principles destitute of virtue as each compo-
ent of the cardiac cycle is functionally dependent on the
ther. Different than 2-dimensional echocardiography,
here crude parameters of cardiac performance such as
jection fraction are used, Doppler echocardiography is able
o detect and quantitatively display minor amplitude and
emporal subtleties that may occur in ventricular mechanical
unction. Traditionally, parameters of diastolic function
ave been derived from Doppler and those of systolic
unction from 2-dimensional variables. This may create the
llusion that individuals have “isolated diastolic dysfunc-
ion.” The interrogation of cardiac function with derived
arameters of deformation such as strain and strain rate
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February 19, 2008:679–89 Unlocking the Mysteries of Diastolic Functiononfirm the illusion despite frequent pronouncement. Mea-
ures of global parameters of myocardial motion using
dvanced speckle tracking algorithms may allow for en-
anced prediction models of LV filling pressure.
The contemporary belief is that the macro architecture of
V myofiber geometry is chiral with the subendocardial
ayer composed in the form of a right-handed helix gradu-
lly evolving into a left-handed helical fiber orientation in
he subepicardial layer. As such, LV fiber orientation is a
unction of transmural location, with the fiber direction
eing predominantly longitudinal in the endocardial and
picardial surfaces and with the helical angle changing
ontinuously between the endocardium and epicardium,
uch that the midwall fibers have a circumferential orienta-
ion forming a sort of equator of the heart (76–78). As with
ontraction, the endocardial and epicardial onset of relax-
tion is temporally discrete beginning in the apical suben-
ocardium just before closure of the aortic valve with
ubepicardial relaxation beginning at the base after aortic
alve closure (79). Different from contraction, however,
elaxation of the helixes is in the opposite direction, apex to
ase for subendocardium and base to apex for subepicar-
ium. The temporal and spatial differences in LV relaxation
re critical for the creation of forces required for diastolic
uction (79). Because of the intrinsic spiral geometry of the
V myofibers, shortening and lengthening of the myocar-
ial wall results in rotary movements. The counter-
irectional rotation of the LV apex with respect to the base
s referred to as LV twist or torsion. By convention, rotation
s described from the apical end of the LV, with clockwise
nd counterclockwise rotations shown in negative and
ositive degrees, respectively (Fig. 8). Our now better
nderstanding of myocardial form and myofiber architec-
ure paralleled with advances in ultrasound signal processing
ave allowed the subtleties of myocardial motion to be
haracterized and quantified (80).
Figure 8 VVI Illustrating the Rotation Motion of the LV Apex
(Left) Systole where the apical rotation is predominantly anticlockwise; (right)
systole where the apical rotation (now untwisting) is predominantly in the clock-
wise direction. LV  left ventricular; VVI  Velocity Vector Image.In the end, the heart is simply a pump, albeit a complex
nd sophisticated one that serves to deliver blood to the
ody. Although we can now begin to decipher the complex
otion needed to complete this task, intriguing are tech-
iques that can also decipher the complexities of the final
ommon purpose of cardiac pump function, blood flow (81).
erhaps systolic and diastolic dysfunction will no longer be
iewed clinically as dichotomous terms but rather voiced as
ust “cardiac dysfunction.” The echocardiography laboratory
ill evolve into a cardiovascular physiology and pathophys-
ology laboratory able to decipher the subtle morphologic
nd physiological characteristics of a heterogeneous group
f cardiovascular diseases (82). We will then be able to
volve a new paradigm of what we define as “disease” with
echophysiology” providing insights allowing for more ac-
ive intervention for prevention strategies. Perhaps in an-
ther decade all inscriptions on the Rosetta Stone will be
eciphered and we will realize that the translation was not
ust that of diastology but rather cardiovascular physiology
nd pathophysiology. Until then. . .
eprint requests and correspondence: Dr. Steven J. Lester,
ardiovascular Diseases, Mayo Clinic Arizona, 13400 East Shea
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